acral malignant melanoma
Conditions
Interventions
Dual-tracing group / experimental group:Laparoscopic pelvic lymph node dissection assisted by dual tracing with indocyanine green and methylene blue.
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed acral malignant melanoma; 2. No relevant treatment received before surgery; 3. Clinical evidence of lymph node metastasis, meeting the guideline indications for pelvic lymph node dissection; 4. No surgical contraindications, normal heart and lung function, physically able to tolerate combined surgery; 5. Obtained informed consent from the patient;
Exclusion criteria
Exclusion criteria: 1.Malignant melanoma of the skin arising from sites other than acral areas. 2.Patients who have received preoperative chemotherapy or radiotherapy, or who are admitted for reoperation due to recurrence. 3.Pregnant or lactating women, or patients with severe mental illness. 4.History of previous pelvic surgery. 5.History of other malignancies within the past five years. 6.History of unstable angina, myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past six months. 7.History of continuous systemic corticosteroid therapy within the past one month. 8.Requirement for concurrent surgical treatment for other diseases. 9.History of iodine allergy, renal insufficiency, or glucose-6-phosphate dehydrogenase deficiency. 10.Patients who refuse laparoscopic surgery or do not undergo surgical treatment for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathology: Total number of lymph nodes, number of visualized lymph nodes, number of non-visualized lymph nodes, number of metastases in visualized/non-visualized lymph nodes, and total number of metastases;Postoperative Recovery Indicators;Fluorescence Intensity and Imaging Performance;Recurrence, Metastasis, and Survival-related Outcomes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Complications;Estimated Blood Loss;ntraoperative Complications;Conversion to Open Surgery and Reason for Conversion;Operative Time;Blood Transfusion Volume; | — |
Countries
China
Contacts
Public ContactYao Liang
Sun Yat-sen University Cancer Center
Outcome results
None listed